Page 2 - Wockhardt

Wockhardt board approves plan to raise Rs 1,000 crore via rights issue

Pharmaceuticals firm Wockhardt Ltd said its board has approved a proposal to raise up to Rs 1,000 crore through a rights issue.

RIL, HDFC, TCS power 673-pts rally in Sensex; Nifty tops 17,800; banks soar

The broader markets underperformed the benchmarks by a wide margin. The BSE MidCap and SmallCap indices ended with meagre gains of 0.05 per cent and 0.4 per cent, respectively.

Stocks to Watch: RIL, Tata Motors, Maruti, NCC, Marico, Hind Zinc, IT stks

Auto majors Maruti and Tata Motors are likely to be in focus today, the former for registering highest exports in a calendar year, and the latter for becoming the second largest PV seller in India.

Wockhardt Q2 net profit zooms over 11-fold to Rs 37.17 crore

Drug firm Wockhardt on Monday reported an over 11-fold jump in its consolidated net profit to Rs 37.17 crore for the quarter ended September 30, 2021.

Stocks to Watch: Aurobindo, Divi's, PTC, Sun Tv, Muthoot Fin, realty shares

Realty stocks on the back of PAG taking a contra call on the sector and corporate earnings will be in focus today

Wockhardt signs pact with Russian co to make 620 mn Sputnik doses in 2 yrs

This is twice the amount of doses Serum Institute of will make of the Russian shot, will take total Sputnik V capacity in India to 1.7 bn doses a year

Wockhardt's growth tonic: Covid vaccines add a third prong to biz strategy

In India, Wockhardt aims to make 2 billion doses of Covid-19 vaccines within the next one or two years but has not disclosed the identity of the tie-ups

Wockhardt plans tie-ups for next-gen Covid-19 vax, aims to make 2 bn doses

Company aims to make 2 billion doses of vaccines in 1 to 2 years

These 20 small-cap stocks appear overbought on the charts. Trade cautiously

Out of these 20 counters, only 4 stocks are showing weakness in the overbought condition and can correct in the days ahead.

Wockhardt's Covid vaccine supply deal with UK Govt extended for 6 months

The drug firm said it has been awarded a six-month extension of its agreement with the UK government

Tata Consultancy Services, Wockhardt lead UK's big Indian investment wins

Tata Consultancy Services (TCS) and pharmaceuticals and biotech major Wockhardt are among the big investment wins being celebrated in the UK

Wockhardt UK vaccine plant evacuated after 'suspicious package'

A "suspicious package" received on Wednesday at a vaccine production facility of India-headquartered bio-pharmaceutical major Wockhardt in the UK led to a partial evacuation of the site

Wockhardt, IIL discuss manufacturing tie-up with US vaccine major Moderna

Around November, IIL had indicated that it was open to discussions with the US major.

Select pharma shares rally; Suven Pharma up 13%, Laurus nears record high

Healthcare companies to post decent growth in revenues in Q3FY21

Wockhardt in talks with global vaccine firms for contract manufacturing

UK site would fill-finish 100 mn doses of AstraZeneca vaccine, has 350 mn dose capacity; Aurangabad can make has 1 bn doses, vaccine raw materials

Wockhardt, Jammu & Kashmir Bank, GE Power, DHFL locked in upper circuit

In the past seven days, GE Power has rallied 80 per cent from its multi-year low of Rs 177.

Healthy growth in India, US helps Dr Reddy's post strong Q2 performance

Wockhardt buy, Covid portfolio aid India business growth

MARKET WRAP: Indices rise for 6th day; Sensex up 304 pts, reclaims 40K

All that happened in the markets today

Wockhardt freezes at 5% lower circuit post weak operating performance in Q1

Company reported negative EBITDA for the quarter at Rs 49 crores as against positive EBITDA of Rs 56 crores in Q1FY20.

Wockhardt reports net profit at Rs 760 cr for June qtr on exceptional items

Drug firm Wockhardt on Saturday reported a consolidated net profit of Rs 759.75 crore for June quarter mainly on account of exceptionalitems in connection with the transfer of a business comprising 62 products and Baddi facility toDr Reddy's Laboratories. The company had posted a net loss of Rs 36.88 crore for April-June 2019-20, Wockhardt said in a filing to BSE. Total income stood at Rs 606.22 crore in the quarter under review. It was Rs 733.66 crore in the year-ago period, the filing added. Wockhardt launchednew chemical entity (NCE) during the quarterin the Indian pharma market. Products have been launched under the tablet and injection category under the brand name 'Emrock O and Emrock', the filing said. The focus on strategic R&D initiatives of the company in the global arena continued to remain one of the key priorities,itadded. It said that divestment of business undertaking to Dr Reddy's Laboratories was accomplished during the quarter and Rs 1,483 crore has been received